Table 1.
Univariate analysis of the predictors in 39 patients with periampullary or pancreatic cancer after operation
| Parameter | Number | Metastasis | DFS | OS | |||
|---|---|---|---|---|---|---|---|
| Hazard ratio(95% CI) | P-value | Hazard ratio(95% CI) | P-value | Hazard ratio(95% CI) | P-value | ||
| Age(years) | 0.969 | 0.75 | 0.326 | ||||
| <65 | 22 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥65 | 17 | 1.369(0.438–4.279) | 1.18(0.426–3.273) | 2.131(0.47–9.656) | |||
| Gender | 0.969 | 0.778 | 0.61 | ||||
| Male | 20 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Female | 19 | 1.023(0.329–3.175) | 1.157(0.419–3.195) | 1.476(0.33–6.599) | |||
| Portal EpCAM + CD45 − count (/5 mL) | 0.077 | 0.037 | 0.282 | ||||
| <60 | 15 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥60 | 24 | 6.363(0.818–49.5) | 8.644(1.133–65.925) | 40.632(0.048–34,694.058) | |||
| Portal EpCAM + CD45 − percentage (×10−4) | 0.06 | 0.019 | 0.742 | ||||
| <24.5 | 26 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥24.5 | 13 | 3.015(0.954–9.53) | 3.447(1.225–9.705) | 1.289(0.284–5.841) | |||
| Peripheral EpCAM + CD45 − count (/5 mL) | 0.034 | 0.007 | 0.175 | ||||
| <97 | 20 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥97 | 17 | 5.278(1.132–24.613) | 7.851(1.747–35.286) | 71.105(0.15–33,666.605) | |||
| Missing | 2 | ||||||
| Peripheral EpCAM + CD45 − percentage (×10−4) | 0.042 | 0.01 | 0.178 | ||||
| <4.4 | 19 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥4.4 | 18 | 4.931(1.063–22.863) | 7.204(1.609–32.256) | 66.136(0.148–29,600.773) | |||
| Missing | 2 | ||||||
| CEA(ng/mL) | 0.927 | 0.749 | 0.858 | ||||
| <5 | 26 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥5 | 11 | 1.058(0.317–3.536) | 0.826(0.257–2.657) | 1.167(0.214–6.375) | |||
| Missing | 2 | ||||||
| CA125(U/mL) | 0.424 | 0.362 | 0.56 | ||||
| <35 | 33 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥35 | 3 | 0.041(0–104.144) | 0.04(0–40.395) | 0.042(0–1789.185) | |||
| Missing | 3 | ||||||
| CA19-9(U/mL) | 0.519 | 0.293 | 0.481 | ||||
| <39 | 10 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥39 | 28 | 1.648(0.361–7.524) | 2.223(0.501–9.855) | 2.14(0.258–17.79) | |||
| Missing | 1 | ||||||
| CA242(U/mL) | 0.027 | 0.003 | 0.063 | ||||
| <3.5 | 20 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥3.5 | 14 | 4.515(1.183–17.234) | 6.937(1.893–25.423) | 7.689(0.897–65.909) | |||
| Missing | 5 | ||||||
| Differentiation | 0.471 | 0.22 | 0.899 | ||||
| Well to moderate | 13 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Others | 26 | 1.619(0.437–5.998) | 2.213(0.623–7.867) | 1.112(0.215–5.751) | |||
| Size | 0.273 | 0.262 | 0.873 | ||||
| ≤2 cm | 1(Referent) | 1(Referent) | 1(Referent) | ||||
| >2 cm | 2.115(0.554–8.079) | 1.949(0.607–6.258) | 0.884(0.197–3.979) | ||||
| Lymphatic metastasis | 0.908 | 0.711 | 0.863 | ||||
| Negative | 21 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Positive | 17 | 0.932(0.284–3.058) | 0.819(0.284–2.361) | 0.876(0.196–3.922) | |||
| Missing | 1 | ||||||
| Neural invasion | 0.265 | 0.202 | 0.392 | ||||
| Negative | 7 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Positive | 30 | 30.99(0.074–12,979.834) | 31.536(0.157–6341.759) | 29.612(0.013–68,797.575) | |||
| Missing | 2 | ||||||
| Lymphovascular tumor embolus | 0.498 | 0.462 | 0.673 | ||||
| Negative | 24 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Positive | 13 | 0.631(0.167–2.384) | 0.647(0.203–2.065) | 1.381(0.309–6.175) | |||
| Missing | 2 | ||||||
| AJCC-stage | 0.908 | 0.711 | 0.863 | ||||
| < II B | 21 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥ II B | 17 | 0.932(0.284–3.058) | 0.819(0.284–2.361) | 0.876(0.196–3.922) | |||
| Missing | 1 | ||||||
| R | 0.75 | 0.74 | 0.511 | ||||
| R0 | 25 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| R1 | 13 | 0.805(0.212–3.05) | 0.821(0.257–2.629) | 1.656(0.368–7.45) | |||
| Missing | 1 | ||||||